E5508 Primary Analysis Clinical Data Description

This data description is for NCT01107626-D2-Dataset.csv. The data in the spreadsheet are the toxicity analysis data for the primary manuscript on NSCLC optimal maintenance therapy analysis results, published in

> Ramalingam S.S., Dahlberg S.E., Belani C.P., Saltzman J.N., Pennell N.A., Nambudiri G.S., McCann J.C., Winegarden J.D., Kassem M.A., Mohamed M.K., Rothman J.M., Lyss A.P., Horn L., Stinchcombe T.E., Schiller J.H.. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. J Clin Oncol. 2019 Sep 10;37(26):2360-2367. doi: 10.1200/JCO.19.01006. Epub 2019 Jul 30. PMID: 31361535; PMCID: PMC7001786.

Pemetrexed or bevacizumab is used for maintenance therapy of advanced no squamous non-small cell lung cancer (NSCLC). The combination of bevacizumab and pemetrexed has also demonstrated efficacy. This study contains two step registration, induction therapy step and maintenance therapy. All patients who were registered to at least one of the steps are included.

Data file description

Field	Name	Description	Coding
1	ID	De-identified case ID number	Numeric code, up to 7 digits
2	toxlabel	Adverse Event Term	Character
3	maxgrade	Patient's maximum CTC Adverse Event (v4.0) Grade	Integer (3-5)
4	step	Study step number	1 = step 1 2 = step 2

- Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).